Clinical trials: Acute Myocardial Infarction
Acute Myocardial Infarction, Acute Coronary Syndrome
Improving Cardiac Rehabilitation Outcomes Through Mobile Case Management (iCARE)
The purpose of this research is to find out if doing cardiac rehab at home, or a mix of cardiac rehab at home and in the clinic, is as effective as coming in to the clinic for cardiac rehab.
- Conditions
- Acute Myocardial Infarction, Acute Coronary Syndrome, Stable Angina Pectoris, Percutaneous Coronary Intervention
- Trial name
- iCARE (NCT04938661)
- Testing
- Center-Based Cardiac Rehab, mHealth, Home-Based Cardiac Rehab
- Where
- 2 sites in United States
- Volunteers
- 206 people
- Sponsor
- Mayo Clinic
Angina, Unstable, Cardiovascular Diseases
IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.
The purpose of this study is to test the impact of pharmacological myocardial metabolic support, in the form of intravenous (IV) glucose, insulin and potassium (GIK), for the treatment of patients with threatened or established…
- Conditions
- Angina, Unstable, Cardiovascular Diseases, Heart Diseases, Coronary Disease
- Trial name
- IMMEDIATE (NCT00091507)
- Testing
- GIK
- Where
- 13 sites in United States
- Volunteers
- 911 people
- Sponsor
- Tufts Medical Center
Acute Myocardial Infarction
Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction
Acute myocardial infarction is characterized by an intense inflammatory response. The degree of the response influences clinical outcome, with 'more' inflammation promoting heart failure.
- Trial name
- VCU-Alpha1RT (NCT01936896)
- Testing
- Alpha 1-Antitrypsin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Virginia Commonwealth University
Myocardial Infarction, Hypercholesterolemia
Alirocumab in Patients With Acute Myocardial Infarction
Phase IV investigator initiated clinical trial to study the effectiveness of alirocumab, an inhibitor of proprotein convertase subtilisin/kexin (PCSK9), versus placebo added to high-intensity statin (atorvastatin 80 mg) in…
- Trial name
- NCT02938949
- Testing
- alirocumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Virginia Commonwealth University
Myocardial Infarction
Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction
Most of the previous data regarding the efficacy of the everolimus-eluting stent (EES) was derived from studies comparing EES with bare metal stent (BMS) or EES with paclitaxel-eluting (PES).
- Trial name
- EVERZOTA (NCT01347554)
- Testing
- Everolimus eluting stent, Zotarolimus eluting stent
- Where
- South Korea
- Volunteers
- 461 people
- Sponsor
- Yonsei University
Atherosclerosis, Myocardial Ischemia
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)
The study is designed to determine whether vorapaxar, when added to the existing standard of care (eg, aspirin, clopidogrel) for preventing heart attack and stroke in patients with acute coronary syndrome, will yield additional…
- Conditions
- Atherosclerosis, Myocardial Ischemia, Myocardial Infarction
- Trial name
- NCT00527943
- Testing
- Vorapaxar
- Volunteers
- 12,944 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Myocardial Infarction
Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction
This study is planned to investigate the impact of Empagliflozin on biomarkers of heart failure in patients with myocardial infarction with and without type 2 diabetes mellitus within 6 months after the event.
- Trial name
- EMMY (NCT03087773)
- Testing
- Empagliflozin 10 mg
- Where
- 11 sites in Austria
- Volunteers
- 476 people
- Sponsor
- Medical University of Graz
Heart Attack
P3AMI Antiplatelet Trial
Major heart attacks are caused by a numerous factors, including sudden clot formation in a coronary artery leading to a blockage and heart muscle death. The clots are largely made of sticky clotting blood cells (platelets).
- Trial name
- NCT02376283
- Testing
- Prasugrel, Clopidogrel, ticagrelor
- Where
- United Kingdom
- Volunteers
- 87 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Acute Myocardial Infarction
Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction
The main objective is to compare a fibrinolytic strategy with an interventional strategy initiated as early as possible, preferably in the pre-hospital phase, with respect to resolution of ST-segment elevation at 120 minutes…
- Trial name
- SWEDES (NCT00806403)
- Testing
- reteplase 10+10 U, primary PCI
- Where
- 5 sites in Sweden
- Volunteers
- 205 people
- Sponsor
- Sahlgrenska University Hospital
Hypoxemia, Trauma
Comparison of Pharyngeal Oxygen Delivery by Different Oxygen Masks
The intent of this study is to determine the difference in pharyngeal oxygen concentration in patients who have a natural airway (not intubated) using commonly available oxygen delivery systems.
- Conditions
- Hypoxemia, Trauma, Acute Myocardial Infarction
- Trial name
- NCT02523586
- Testing
- Oxygen administration
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Cost Sharing, Acute Coronary Syndrome
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes.
- Trial name
- ARTEMIS (NCT02406677)
- Testing
- Study voucher card
- Where
- 272 sites in United States, Puerto Rico
- Volunteers
- 11,001 people
- Sponsor
- AstraZeneca
Acute Coronary Disease, Angina Unstable
Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a…
- Trial name
- CURRENT/OASIS7 (NCT00335452)
- Testing
- Clopidogrel, acetylsalicyclic acid (ASA)
- Where
- 38 sites in United States, Argentina and 36 more
- Volunteers
- 25,086 people
- Sponsor
- Sanofi
Acute Coronary Syndromes
A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction
The purpose of this trial is to investigate the potential benefits/risks regarding pretreatment with prasugrel in non-ST-elevation myocardial infarction (NSTEMI) participants with elevated troponin scheduled for coronary…
- Trial name
- ACCOAST (NCT01015287)
- Testing
- Prasugrel
- Where
- 153 sites in Austria, Belgium and 17 more
- Volunteers
- 4,033 people
- Sponsor
- Eli Lilly and Company
ST Segment Elevation Acute Myocardial Infarction
Anakinra to Prevent Post-infarction Remodeling
Thousands of patients die daily from early and late complications of a heart attack (acute myocardial infarction, AMI). Patients surviving AMI remain at high risk of death from adverse cardiac remodeling (dysfunction and…
- Trial name
- VCU-ART (NCT00789724)
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Virginia Commonwealth University
Acute Coronary Syndrome, Myocardial Infarction
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
- Trial name
- NCT00809965
- Testing
- Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Standard of care
- Where
- 556 sites in United States, Argentina and 41 more
- Volunteers
- 15,526 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Coronary Syndrome
The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g.
- Trial name
- SOLID-TIMI 52 (NCT01000727)
- Testing
- Darapladib 160 mg, Standard Therapy
- Where
- 914 sites in United States, Argentina and 34 more
- Volunteers
- 13,026 people
- Sponsor
- GlaxoSmithKline
Myocardial Infarction, Arrhythmias
T-Wave Alternans in Acute Myocardial Infarction: An Evaluation of the Time of Testing on Its Prognostic Accuracy
T-wave alternans is an electrocardiographic finding that has been shown to predict the occurrence of future cardiac arrhythmias in patients who have had a heart attack.
- Trial name
- NCT00589849
- Testing
- T-wave Alternans
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Creighton University
Acute Coronary Syndrome
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots.
- Trial name
- PLATO (NCT00391872)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 672 sites in United States, Argentina and 42 more
- Volunteers
- 18,624 people
- Sponsor
- AstraZeneca
Acute Myocardial Infarction
Effects of Cardiac Rehabilitation on High Mobility Group Box-1 Levels After Acute Myocardial Infarction
This purpose of this study is to examine the relationship between HMGB-1 and postinfarction predictors of outcome such as cardiopulmonary and echocardiographic parameters before and after a 6-month exercise-based cardiac…
- Trial name
- NCT00755131
- Testing
- Exercise-based Cardiac Rehabilitation program
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- Federico II University
Acute Myocardial Infarction
Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)
This study will evaluate change in heart muscle function from baseline to three months and twelve months in participants who present with a heart attack and a completely occluded coronary artery.
- Trial name
- NCT01324453
- Testing
- Post Conditioning + Primary PCI, Standard Primary PCI
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Minneapolis Heart Institute Foundation